Your doctor looked at your labs and said you’re fine.
Your TSH is normal. Your T4 is normal. Everything is within range.
And you still can’t lose weight, can’t think straight, can’t get through the afternoon without collapsing. You’re exhausted in a way that sleep doesn’t fix.
That gap between “normal” and “feeling well” is exactly where Dr. Sharmistha Trivedi practices medicine.
Dr. Trivedi is an integrative endocrinologist with 20 years of experience, medical director at Casad Health and Wellness in Dallas, and one of the clearest clinical voices I’ve encountered on the intersection of thyroid function, hormonal health, and the GLP-1 conversation that is dominating women’s health right now.
In this conversation, we cover the full picture: why the normal TSH range is not the optimal TSH range, why starting a GLP-1 medication without fixing your hormones first is the wrong order of operations, how to think about perimenopause as a neuroendocrine vulnerability window rather than just a reproductive event, and what combination thyroid therapy actually does that T4 alone cannot.
If you have been told your labs are normal and you still feel terrible, this is for you.
Medical note: This content is educational. Hormone therapy, thyroid management, and GLP-1 medications all require individualized evaluation by a qualified physician. Do not start, stop, or adjust any medication based on this content alone.
Table of Contents
→ Perimenopause as a Neuroendocrine Vulnerability Window
→ Premature Ovarian Insufficiency: What It Is and Why Birth Control Misses the Point
→ The Right Order: Hormones Before GLP-1
→ GLP-1 Medications in Menopause: What Works, What Doesn’t, How to Wean Off
→ Thyroid: The Normal Range Isn’t the Optimal Range
→ T3 Is Not Optional: The Case for Combination Thyroid Therapy
→ MPA vs Bioidentical Progesterone: A Clinical Case That Says Everything
→ The Underlying Root Causes No Medication Fixes
→ FAQ
Time Stamps
[00:00] Introduction: what integrative endocrinology means and how Dr. Trivedi evolved her practice
[03:30] Perimenopause as neuroendocrine immunologic vulnerability — why every system shifts at once
[06:00] Premature ovarian insufficiency: definition, prevalence, and why it’s devastating at any age
[09:00] Dr. Anna’s own POI diagnosis at 39 and ovarian resuscitation
[11:30] Why birth control pills are the wrong answer for POI and early menopause
[14:00] Mental readiness as a clinical factor in starting cyclic hormone therapy
[17:00] The perimenopause transition: why no two women need the same protocol
[20:00] Cardiometabolic risk and weight gain without doing anything differently
[22:30] The case for hormones first, GLP-1 second — and why the order matters
[26:00] How Dr. Trivedi structures a GLP-1 program: body composition, nutrition, exercise
[30:00] GI side effects: how to manage them and when they signal the wrong medication
[33:00] Weaning off GLP-1 without rebound: the three-month chunk framework
[37:00] The root cause question: why is America the most obese nation?
[40:00] Eating for immunity and the small actionable steps that actually stick
[43:30] Microdosing vs therapeutic dosing of GLP-1 medications
[47:00] Thyroid: why TSH 2.0 or lower is the target for midlife women
[51:00] The full thyroid panel: TSH, free T4, free T3, antibodies
[54:30] T3 is not optional: why combination therapy outperforms T4 alone
[58:00] Thyroid medication options: Synthroid + Cytomel, Armour, NP, compounded, Tirosint
[62:00] The clinical case: medroxyprogesterone vs bioidentical progesterone
[67:00] MPA — the most toxic progestin available and why its name is dangerously misleading
[70:00] Does a woman without a uterus need progesterone?
Perimenopause as a Neuroendocrine Vulnerability Window
Most women are taught that perimenopause is a hormonal transition. Dr. Trivedi describes it more precisely as a period of neuroendocrine immunologic vulnerability.
That distinction matters. It means that during the years leading up to menopause, virtually every system in the body is shifting simultaneously:
Neurotransmitter balance changes
Sleep architecture changes
Insulin efficiency changes
Immune regulation changes
Cardiovascular risk trajectory changes
Metabolic rate and fat distribution change
This is not a decline. It is a recalibration. And the way you support your body through it determines how you come out the other side.
“This is a period of neuroendocrine vulnerability. Every single aspect of your physiology is shifting — the way we think, our sleep architecture, our metabolism, our insulin efficiency. Every single system is affected.”
Dr. Trivedi’s approach in this window: listen to what each woman’s body is telling you. Do not apply a protocol. Layer in what is actually missing, when the body signals it is needed, at the dose the body can respond to.
And critically, this is not your body failing you. It is a normal transition that has been badly underserved by conventional medicine for too long.
Premature Ovarian Insufficiency: What It Is and Why Birth Control Misses the Point
Premature ovarian insufficiency (POI) is defined as loss of normal ovarian function before age 40. It is not rare, and it is not just a reproductive problem.
Dr. Anna Cabeca shares her own experience: diagnosed at 39, told she would never conceive again, she went on to reverse the diagnosis naturally and conceive the child she was told she’d never have. Both physicians have seen this pattern in their practices.
The most common medical response to POI is to put the woman on a birth control pill. Both Dr. Trivedi and Dr. Cabeca challenge this approach:
Birth control pills contain synthetic progestins, not bioidentical progesterone. The neuroprotective, anti-inflammatory, and hormonal cascade effects of progesterone are absent.
Birth control suppresses the body’s own testosterone production
The effects of long-term birth control on adrenal function are not well-studied — the data simply does not exist
A woman on birth control is not cycling in any physiologically meaningful sense
Dr. Trivedi’s nuanced position: for younger women who are not mentally ready to engage with a cyclic bioidentical hormone protocol, birth control may serve a short-term purpose. But the goal is to move toward bioidentical estradiol and progesterone as soon as the woman is ready.
"If you’re not ready to deal with it, birth control is okay. But when we’re ready to cycle estrogen and progesterone, that is an option. It takes time, mental energy, and addressing something that we might not be ready for. Changing the mindset is often the most important thing"
The Right Order: Hormones Before GLP-1
This is one of the most clinically important points in the conversation — and one that is being routinely skipped in practices prescribing GLP-1 medications.
Dr. Trivedi is direct: for women who are in active perimenopause or menopause, starting a GLP-1 medication without first optimizing hormones is likely to produce an incomplete, unsustainable result.
Why? Because in a body that is estrogen-deficient, progesterone-deficient, and potentially thyroid-compromised:
Muscle mass is already being lost at an accelerated rate
Cortisol and inflammatory signals are elevated
Insulin resistance may be more hormonal than metabolic in origin
The gut changes associated with menopause affect how the GLP-1 medication interacts with the digestive system
A GLP-1 medication applied to a hormonally depleted body is just starving that body more efficiently. It is not building resilience. It is building further insufficiency.
Dr. Trivedi’s protocol: spend at least six months optimizing progesterone, estradiol, thyroid, and testosterone before introducing a GLP-1. In many cases, the majority of women see meaningful metabolic shifts from hormone optimization alone before the GLP-1 is ever needed.
“If you have a woman who is in florid perimenopause or menopause, you probably have to fix some of those hormones first. Otherwise the GLP-1 is just going to be starving our body. We’re not going to be building resilience. We’re going to be building further insufficiency if we don’t fix certain things first.”
GLP-1 Medications in Menopause: What Works, What Doesn’t, and How to Wean Off
Dr. Trivedi was one of the study site physicians for first and second generation GLP-1 medications at UT Southwestern. She brings both clinical trial experience and 20 years of patient care to this conversation.
When GLP-1 Medications Make Sense
For women who have optimized their hormones and are still dealing with insulin resistance, elevated cardiovascular risk markers, pre-diabetes, or persistent weight that is not moving — GLP-1 medications can be a meaningful addition to care.
How Dr. Trivedi Implements Them
- Start at the lowest dose — always
- Do not force four-week dose escalations. Some patients need six to eight weeks at each level
Body composition monitoring at baseline, six months, and one year to ensure muscle mass is preserved
A structured exercise and nutrition plan as a non-negotiable before starting
Monthly check-ins with body weight and composition
GI side effects that worsen rather than improve at higher doses signal the wrong medication for that patient
The Weaning Question: Are These Forever?
Most patients will not wean off quickly. Attempting to do so in three months almost always leads to rebound. Dr. Trivedi’s framework:
Think in three-month chunks, not weeks
Total time on the medication is usually longer than the patient imagined at the start — set that expectation before prescribing
Some patients can extend the dosing interval rather than lowering the dose (weekly to every ten days, then every fourteen days)
Women with type 2 diabetes or significant cardiometabolic comorbidities will likely need this long-term — that is appropriate chronic disease management, not failure
Goal weight conversations must happen before starting: most patients have a number in their head that is too low for healthy body composition at their age
“This is where I am right now. Is this where we’re going to be forever? No. But this is where we are now. So let’s get in, see what we can fix, and move on from there. It’s not a failure. Your body is not failing you.”
Thyroid: The Normal Range Isn’t the Optimal Range
One of the most common dismissals in women’s healthcare: “Your TSH is normal.”
Normal and optimal are not the same thing.
Standard lab normal ranges for TSH typically run from approximately 0.45 to 4.5. A TSH of 4.0 is technically within range. For a midlife woman with fatigue, brain fog, difficulty with weight, and low motivation — a TSH of 4.0 is almost certainly not her optimal range.
Dr. Trivedi’s optimal TSH target for midlife women: 2.0 or lower. Some women feel their best closer to 1.5. The only way to know is to treat to symptoms, not to a number on a reference range.
What Dr. Trivedi draws on baseline thyroid evaluation:
TSH
Free T4
Free T3
Thyroid antibodies (depending on family history and physical exam findings)
Signs of subclinical hypothyroidism are worth looking for even with a “normal” TSH:
Fatigue that is disproportionate to what sleep and stress explain
Low motivation and reduced drive
Weight that resists change despite effort
Dry skin, hair thinning, feeling cold when others are comfortable
Slightly dull or sullen skin quality on exam
“A TSH of 2.0 or lower is ideal for my midlife women. That’s where we kind of feel our best. And yes, this is where that clinical gray area of subclinical hypothyroidism comes in — where we need to give a little thyroid hormone to just boost our own production and fix the issue. That’s where personalization matters.”
T3 Is Not Optional: The Case for Combination Thyroid Therapy
In conventional endocrinology training, T3 — the active form of thyroid hormone — is considered largely irrelevant. The prevailing model: prescribe T4, the body will convert it to T3 as needed.
Dr. Trivedi was trained the same way. She has since moved well past it.
Her clinical experience: outcomes are significantly better when both T4 and T3 are provided simultaneously rather than relying on the body’s conversion pathway.
This matters because in many women — particularly in perimenopause and menopause, under chronic stress, or with gut dysfunction — the conversion of T4 to active T3 is impaired. You can have a normal TSH and T4, and a free T3 sitting at the bottom of the reference range. That woman is functionally hypothyroid at the cellular level even when her labs appear normal.
Thyroid options Dr. Trivedi uses:
Synthroid (T4) + Cytomel (T3) — separate prescriptions, individually dosed
Armour Thyroid — desiccated glandular, contains both T4 and T3 in natural ratio
NP Thyroid — similar glandular composition (insurance coverage has become more challenging)
Compounded thyroid — allows precise individualized T4:T3 ratio
Tirosint — a low-excipient T4 option for those with filler sensitivities
“My outcomes are so much better clinically when we have both T4 and T3 implemented at the same time. In my endocrine training, T3 had no value, and you didn’t even have to measure it. That’s dangerously close to where we are now as far as time points. But it’s game-changing for patients.”
MPA vs Bioidentical Progesterone: A Clinical Case That Says Everything
Dr. Trivedi shares a case that illustrates exactly what happens when hormone therapy is implemented without adequate clinical oversight.
A 55-year-old woman came to her practice after being managed by an online hormone clinic. She had been placed on a high-dose estradiol patch changed every two days, along with medroxyprogesterone acetate (MPA). For six to eight weeks she had daily vaginal bleeding. The online clinic told her this was normal and to wait it out.
It was not normal. It was a predictable consequence of high-dose estrogen without adequate endometrial protection — and MPA is not bioidentical progesterone despite having the word “progesterone” in its name.
What Dr. Trivedi did:
Stopped everything and allowed a short washout period
Confirmed no intrinsic bleeding without the hormones
Started compounded bi-est (estradiol + estriol) transdermally
Added micronized bioidentical progesterone
Layered in thyroid hormone — TSH was 3.8, free T3 and free T4 at the bottom of normal range
Added a small amount of testosterone
That woman told her: “You gave me my life back. You gave me my brain back.”
The key distinction this case illustrates: medroxyprogesterone acetate (MPA) has the word progesterone in its name and is not progesterone. Bioidentical progesterone — micronized progesterone, P4 — has a completely different molecular structure, receptor activity, and safety profile.
If you are currently taking medroxyprogesterone acetate (Provera, Depo-Provera, or MPA in a combination pill), ask your physician about transitioning to bioidentical micronized progesterone. Do not stop or change any medication without medical supervision.
The Underlying Root Causes No Medication Fixes
Both physicians return to a question that GLP-1 medications, hormone therapy, and thyroid support do not answer: what happened to the body’s own systems in the first place?
Neither physician has a complete answer. Both point in the same direction:
Ultra-processed food that has dismantled the gut microbiome
Glyphosate and agricultural pesticide exposure affecting gut integrity and hormonal signaling
Endocrine-disrupting chemicals in plastics, personal care products, and food packaging
Blue light and EMF exposure affecting circadian regulation and sleep
Chronic stress patterns that dysregulate cortisol and suppress immune function
A medical system that treats symptoms in isolation rather than looking for the thread connecting them
Dr. Trivedi’s clinical philosophy: take small, actionable steps that someone can actually stick to. A trauma surgeon on a 24-hour shift cannot come home to a chicken and broccoli meal. But she can prep it the night before.
“Am I going to ask you to cut out all of the endocrine disruptors in your life? No. But could we maybe slow down on buying Cheez-Its for the next month? Probably. Could we work on baby morning movement? We just have to work in what is possible.”
FAQ:
Q: Should I fix my hormones before starting a GLP-1 medication?
A: According to Dr. Sharmistha Trivedi, yes — at least for most women in perimenopause or menopause. GLP-1 medications work by suppressing appetite and improving insulin sensitivity, but in a body that is hormonally depleted they primarily accelerate muscle mass loss and do not address the hormonal drivers of weight gain. Dr. Trivedi’s recommended approach: spend at least six months optimizing estradiol, progesterone, thyroid, and testosterone before introducing a GLP-1. Many women see significant metabolic improvement from hormone optimization alone.
Q: What is the optimal TSH level for women in menopause?
A: The standard lab normal range for TSH (approximately 0.45 to 4.5) is not the same as the optimal range. For midlife women, Dr. Trivedi targets a TSH of 2.0 or lower. Some women feel best closer to 1.5. A TSH at the high end of normal — such as 3.8 to 4.2 — can produce significant hypothyroid symptoms in perimenopausal and menopausal women even when technically within normal limits. Treatment to optimization, not to the reference range, is the goal.
Q: Do I need T3 if my T4 levels are normal?
A: Potentially yes. T4 is a pro-hormone that must be converted to active T3 to be usable at the cellular level. Many women — particularly those under chronic stress, with gut dysfunction, or in hormonal transition — have impaired T4 to T3 conversion. A normal T4 does not guarantee adequate T3 at the tissue level. Dr. Trivedi finds significantly better clinical outcomes when T3 is provided alongside T4, either through combination prescriptions, desiccated glandular thyroid, or compounded formulations.
Q: What is the difference between medroxyprogesterone and bioidentical progesterone?
A: Medroxyprogesterone acetate (MPA) — found in Provera and some combination HRT formulations — is a synthetic progestin, not progesterone. Despite the name, it has a different molecular structure and receptor activity than the progesterone produced by the human ovary. Bioidentical progesterone (micronized progesterone, P4) has the same molecular structure as endogenous progesterone and a substantially better safety and tolerability profile. MPA was the progestin used in the Women’s Health Initiative; bioidentical progesterone was not.
Q: How long do you need to stay on GLP-1 medications like Ozempic or Mounjaro?
A: Most patients will need to remain on GLP-1 medications longer than they initially expect. Rapid weaning over three months almost always results in significant rebound weight gain. Dr. Trivedi’s weaning framework uses three-month chunks with gradual dose reduction or interval extension. Some patients with type 2 diabetes or significant cardiometabolic conditions will need these medications long-term. This is not a failure — it is appropriate management of a chronic condition.
Q: What is premature ovarian insufficiency and can it be reversed?
A: Premature ovarian insufficiency (POI) is loss of normal ovarian function before age 40. In some cases ovarian function can recover or be supported. Dr. Anna Cabeca was diagnosed with POI at 39 and subsequently conceived naturally after reversing the hormonal deficit through an integrative approach. The immediate clinical priority is replacing estradiol and progesterone to protect brain, bone, cardiovascular, and metabolic health. Emerging interventions including PRP and exosome injections into ovarian tissue are also being studied.
Q: Why do women gain weight in menopause even without changing their diet?
A: Multiple mechanisms work together: as estrogen and progesterone decline, insulin and cortisol increase, shifting fat storage toward the abdomen. Thyroid function may be suboptimal. Muscle mass declines as anabolic hormones decrease. Sleep disruption worsens metabolic regulation. And the gut microbiome shifts significantly in menopause. A strategy that worked in your 30s is operating in a completely different hormonal environment. Optimizing hormones and thyroid is the foundational step before metabolic medications are considered.
Q: What is integrative endocrinology?
A: Integrative endocrinology combines evidence-based conventional medicine with a whole-body approach to hormonal health. Where conventional endocrinology tends to treat individual hormones in isolation, integrative endocrinology looks at how hormones interact with each other, how they are affected by nutrition, stress, sleep, and gut health, and what each individual patient actually needs rather than what the standard protocol dictates. Practitioners like Dr. Trivedi use the same labs and medications as conventional endocrinologists but with a broader clinical lens and a personalized, layered approach.
Resources Mentioned
- Jeet Victory Yoga — Dr. Trivedi’s yoga studio
M Factor / Menopause Documentary — screening where Dr. Anna and Dr. Trivedi met
UT Southwestern — where Dr. Trivedi trained and participated in early GLP-1 clinical trials
Dr. Anna Cabeca’s Balance cream (bioidentical progesterone + pregnenolone)
Connect With Dr. Shamita Trivedi
Connect With Dr. Anna
Note: For women experiencing symptoms of thyroid dysfunction, hormone imbalance, or cardiometabolic weight issues, finding a physician trained in integrative endocrinology or functional medicine with hormone expertise is the recommended starting point.
